AMGN•benzinga•
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Summary
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day."
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 21, 2024 by benzinga